TAP PARTNER NEWS DURING ASH: DEC 2021
TAP PARTNER NEWS DURING ASH: DEC 2021
Secura Bio Announces the Presentation of New COPIKTRA® (duvelisib) Data for the Treatment of Patients with Relapsed or Refractory PTCL
SUMMERLIN, Nev., Dec. 14, 2021 - Secura Bio, Inc., an integrated pharmaceutical company dedicated to the worldwide development and commercialization of impactful oncology therapies, today announced that new data for the treatment of relapsed or refractory (r/r) PTCL patients with COPIKTRA (duvelisib) were presented at the 63rd annual meeting of the American Society of Hematology (ASH) in Atlanta, Georgia.
Kymera Therapeutics Presents Positive Preclinical Data on Selective STAT3 Degraders for Hematological and Solid Tumor Malignancies at 63rd American Society of Hematology (ASH) Annual Meeting
WATERTOWN, Mass., Dec. 13, 2021 - Kymera Therapeutics, Inc. (NASDAQ: KYMR), a biopharmaceutical company advancing targeted protein degradation to deliver novel, small molecule protein degrader therapeutics, today announced the company presented new preclinical data for its STAT3 degraders, including its first-in-class KT-333 STAT3 degrader, at the virtual 63rd American Society of Hematology (ASH) Annual Meeting taking place from December 11 – 14, 2021 in Atlanta, GA and virtually.
Fred Hutchinson Cancer Research Center, in Partnership with Sutro Biopharma, to Present at ASH 2021
SOUTH SAN FRANCISCO, Calif, Dec. 13, 2021 – Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and autoimmune therapeutics, today announced that its research collaborators at the Fred Hutchinson Cancer Research Center presented nonclinical data of STRO-002 and STRO-001 in two oral presentations at the 63rd American Society of Hematology Annual Meeting (ASH 2021) in Atlanta, Georgia. The research was conducted by investigators from the laboratory of Soheil Meshinchi, M.D., Ph.D., Professor, Clinical Research Division at Fred Hutchinson Cancer Research Center and Professor, Division of Pediatric Hematology-Oncology at the University of Washington School of Medicine.
Affimed Shares Preclinical Data on Innate Cell Engagers AFM28 and AFM13 at the 63rd ASH Annual Meeting
Heidelberg, Germany, December 13, 2021 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today presented preclinical data from two of their Innate Cell Engager (ICE®) programs at the 63rd American Society of Hematology Annual Meeting (ASH). The poster presentations included preclinical proof-of-concept data on AFM28, for which Affimed recently revealed the target and indication. The program is in development for the treatment of Acute Myeloid Leukemia and other CD123+ hematologic malignancies. The second poster presentation provided data on the activity of AFM13 pre-complexed to NK cells after cryopreservation, demonstrating the potential to develop AFM13 as an off-the-shelf chimeric antigen receptor (CAR)-like NK cell product.
Ryvu Therapeutics Presents Clinical and Translational Data Updates at the 63rd American Society of Hematology Annual Meeting
Krakow, Poland – 13 December 2021 – Ryvu Therapeutics [WSE: RVU], a clinical-stage drug discovery and development company focusing on novel small molecule therapies that address emerging targets in oncology, today announced updated clinical and preclinical data demonstrating the single-agent activity of its lead oncology drug candidate RVU120 at the 63rd American Society of Hematology Annual Meeting, held December 11 – December 14, 2021, in Atlanta.
Kura Oncology Reports Preclinical Data Highlighting Synergistic Activity of Menin Inhibitor KO-539 in Combination with Venetoclax
SAN DIEGO, Dec. 13, 2021 - Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced the presentation of new preclinical data for KO-539, the Company’s oral, potent and selective menin inhibitor, and its potential for synergistic activity in combination with venetoclax, a current standard of care in the treatment of patients with acute myeloid leukemia (AML).
MorphoSys presents latest data from the Phase 2 MANIFEST Study evaluating the potential of pelabresib in the treatment of myelofibrosis
December 12, 2021 - MorphoSys AG (FSE: MOR; NASDAQ: MOR) presented the latest data from the ongoing MANIFEST study, an open-label, Phase 2 clinical trial of pelabresib, an investigational BET inhibitor, in patients with myelofibrosis, a rare bone marrow cancer for which only limited treatment options are available. These latest results, which included more patients and longer-term follow-up than previously reported data, suggest the potential of pelabresib in the treatment of myelofibrosis. These findings were presented during poster and oral sessions at the 63rd American Society of Hematology Annual Meeting and Exposition (ASH 2021), held December 11 - 14, 2021 in Atlanta, Georgia and virtually.
NexImmune Announces Preliminary Phase 1/2 NEXI-002 Results in Patients with Multiple Myeloma
GAITHERSBURG, Md., Dec. 12, 2021 - NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today announced preliminary Phase 1/2 results from an ongoing study of NEXI-002, a patient-derived multi-antigen-specific CD8+ T cell treatment for patients with relapsed/refractory multiple myeloma who have failed ≥3 prior lines of therapy. The data on low doses of NEXI-002, presented at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition, showed a promising safety and tolerability profile and evidence of immunologic and clinical activity.
X4 Pharmaceuticals Presents New Clinical Data at ASH 2021 Further Supporting Potential of Mavorixafor + Ibrutinib to Treat Patients with Double-Mutation Waldenström’s Macroglobulinemia
BOSTON, Dec. 11, 2021 - X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel CXCR4-targeted small molecule therapeutics to benefit people with immune system dysfunction, today announced new positive efficacy and safety data from the ongoing Phase 1b clinical trial of its lead candidate mavorixafor, in combination with ibrutinib, for patients with Waldenström’s macroglobulinemia (WM) and confirmed MYD88 and CXCR4 mutations. These study results were reported today in a poster presentation at the American Society of Hematology (ASH) Annual Meeting, taking place both virtually and in person in Atlanta, GA, December 11-14, 2021.
Yescarta® Is First CAR T-cell Therapy to Report Five-Year Survival Data From Pivotal Study Showing Durable Long-Term Survival in Patients With Refractory Large B-cell Lymphoma
December 11 2021 - SANTA MONICA, Calif. - Kite, a Gilead Company (Nasdaq: GILD), today announced five-year follow-up data from the pivotal ZUMA-1 trial of Yescarta® (axicabtagene ciloleucel) in adult patients with refractory large B-cell lymphoma (LBCL). Among all patients treated with Yescarta, the five-year overall survival (OS) rate was 42.6%. Among patients who had a complete response (CR), the five-year OS rate was 64.4% and median survival time has yet to be reached. Among treated patients alive at five years, 92% have received no additional treatment since their one-time infusion of Yescarta, suggestive of a cure for these patients. The data were presented today at the 63rd American Society of Hematology (ASH) Annual Meeting & Exposition.
New Research on Magrolimab Provides Key Insights as Gilead Rapidly Expands Research in AML
FOSTER CITY, Calif. & SANTA MONICA, Calif. November 04, 2021 - Gilead Sciences, Inc. (Nasdaq: GILD) today announced that data at the 63rd American Society of Hematology (ASH) Annual Meeting & Exposition (December 11-14) will showcase early-stage research on magrolimab, an investigational CD47 inhibitor, both in an oral session and in an ASH-EHA Joint Symposium. In addition, four trials in progress will be on display highlighting ongoing clinical trials of magrolimab in myeloma, AML and MDS. Gilead acquired Forty Seven back in 2020 and is continuing development of magrolimab in multiple blood cancer indications.
argenx to Present Clinical Update on Cusatuzumab at 63rd Annual ASH Meeting
argenx a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer presented clinical data for cusatuzumab, an investigational SIMPLE Antibody™ targeting CD70, an immune checkpoint target, at the virtual 63rd American Society of Hematology (ASH) Annual Meeting taking place from December 11 – 14, 2021 in Atlanta, GA.
Jazz Pharmaceuticals to Present Data Showcasing Vyxeos Clinical Advances at ASH 2021 Annual Meeting
DUBLIN, Nov. 4, 2021 - Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that 10 new data abstracts from studies exploring Vyxeos development in acute myeloid leukemia (AML) and higher risk myelodysplastic Syndrome (MDS) will be presented at the 63rd American Society of Hematology (ASH) Annual Meeting, which will be held December 11-14, 2021. This includes presentations from investigator-sponsored trials and presentations from collaboration studies with The University of Texas MD Anderson Cancer Center (MD Anderson).